- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
11
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
11 companies
Merck
Market Cap: US$278.8b
Operates as a healthcare company worldwide.
MRK
US$114.62
7D
-0.7%
1Y
43.6%
Illumina
Market Cap: US$19.8b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$125.44
7D
-5.5%
1Y
61.6%
Exelixis
Market Cap: US$11.9b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$46.05
7D
3.8%
1Y
23.8%
ACADIA Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.11
7D
4.0%
1Y
49.1%
ADMA Biologics
Market Cap: US$2.5b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$11.08
7D
3.2%
1Y
-50.4%
Aurinia Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$16.14
7D
2.0%
1Y
99.3%
Theravance Biopharma
Market Cap: US$853.2m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.31
7D
-2.8%
1Y
71.0%
CorMedix
Market Cap: US$587.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.33
7D
2.8%
1Y
-19.9%
Abeona Therapeutics
Market Cap: US$320.2m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.52
7D
2.6%
1Y
2.4%
Compugen
Market Cap: US$267.6m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.92
7D
1.0%
1Y
97.3%
Oramed Pharmaceuticals
Market Cap: US$157.7m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.84
7D
-0.5%
1Y
67.0%